Year: 2017
Type: article
Abstract: Mutations in the glucocerebrosidase 1 (GBA1) gene are related to both Parkinson disease (PD) and Gaucher disease (GD). In both cases, the condition is associated with deficiency of glucocerebrosidase (GCase), the enzyme encoded by GBA1. Ambroxol is a small molecule chaperone that has been shown in mice to cross the blood-brain barrier, increase GCase activity and reduce alpha-synuclein protein levels. In this study, we analyze the effect of ambroxol treatment on GCase activity in healthy nonhuman primates. We show that daily administration of ambroxol results in increased brain GCase activity. Our work further indicates that ambroxol should be investigated as a novel therapy for both PD and neuronopathic GD in humans.
Source: Synapse
DOI: 10.1002/syn.21967
Institutions: UCL Queen Square Institute of Neurology, University College London, Motac Neuroscience (United Kingdom), Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Laboratory Animal Science, Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $1,850
OpenAlex ID: W2592033002
